Primary |
Multiple Myeloma |
29.8% |
Acute Lymphocytic Leukaemia |
15.0% |
Non-hodgkin's Lymphoma |
12.2% |
Drug Use For Unknown Indication |
7.9% |
Chemotherapy |
7.1% |
Lymphoma |
4.3% |
B Precursor Type Acute Leukaemia |
3.2% |
Hodgkin's Disease |
2.1% |
Prophylaxis |
1.9% |
B-cell Lymphoma |
1.7% |
Breast Cancer |
1.7% |
Corneal Epithelium Defect |
1.7% |
Leukaemia |
1.7% |
Premedication |
1.5% |
Product Used For Unknown Indication |
1.5% |
Prophylaxis Of Nausea And Vomiting |
1.5% |
Cataract Operation |
1.3% |
Histiocytosis Haematophagic |
1.3% |
Mantle Cell Lymphoma Stage Iv |
1.3% |
Pancreatic Carcinoma |
1.3% |
|
Neutropenia |
17.7% |
Progressive Multiple Sclerosis |
7.6% |
Corneal Deposits |
5.1% |
Deep Vein Thrombosis |
5.1% |
Myelodysplastic Syndrome |
5.1% |
Pneumonia |
5.1% |
Renal Failure Acute |
5.1% |
Staphylococcal Infection |
5.1% |
Thrombocytopenia |
5.1% |
Vomiting |
5.1% |
Drug Toxicity |
3.8% |
Hyperglycaemia |
3.8% |
Melaena |
3.8% |
Pulmonary Embolism |
3.8% |
Sinus Tachycardia |
3.8% |
Tremor |
3.8% |
White Blood Cell Count Decreased |
3.8% |
Abdominal Pain Upper |
2.5% |
Bradycardia |
2.5% |
Chronic Myeloid Leukaemia |
2.5% |
|
Secondary |
Multiple Myeloma |
59.4% |
Drug Use For Unknown Indication |
11.0% |
Acute Lymphocytic Leukaemia |
6.8% |
Mantle Cell Lymphoma |
3.3% |
Prophylaxis |
3.0% |
B-cell Lymphoma |
3.0% |
Non-hodgkin's Lymphoma |
1.8% |
Diffuse Large B-cell Lymphoma |
1.5% |
Burkitt's Lymphoma |
1.3% |
Amyloidosis |
1.0% |
Hypertension |
1.0% |
Breast Cancer |
1.0% |
Premedication |
0.8% |
Prostate Cancer |
0.8% |
Pain |
0.8% |
Diabetes Mellitus |
0.7% |
Lymphoma |
0.7% |
Testis Cancer |
0.7% |
Pneumonia Bacterial |
0.7% |
Chronic Lymphocytic Leukaemia |
0.6% |
|
White Blood Cell Count Decreased |
13.0% |
Thrombocytopenia |
10.0% |
Vomiting |
8.3% |
Sepsis |
6.2% |
Pneumonia |
5.9% |
Death |
4.8% |
Pyrexia |
4.7% |
Renal Failure |
4.6% |
Weight Decreased |
4.6% |
Pulmonary Embolism |
4.2% |
Urinary Tract Infection |
4.1% |
Platelet Count Decreased |
3.7% |
Disease Progression |
3.6% |
Septic Shock |
3.6% |
Tumour Lysis Syndrome |
3.4% |
Renal Failure Acute |
3.2% |
Osteonecrosis |
3.0% |
Respiratory Failure |
3.0% |
White Blood Cell Count Increased |
3.0% |
Hyperglycaemia |
2.9% |
|
Concomitant |
Drug Use For Unknown Indication |
28.6% |
Multiple Myeloma |
17.5% |
Non-small Cell Lung Cancer |
8.6% |
Prophylaxis |
6.5% |
Breast Cancer |
5.8% |
Premedication |
5.5% |
Pain |
4.9% |
Hypertension |
2.6% |
Nausea |
2.4% |
Colorectal Cancer Metastatic |
2.4% |
Prophylaxis Of Nausea And Vomiting |
2.0% |
Gastric Cancer |
1.8% |
Antiemetic Supportive Care |
1.7% |
Glioblastoma Multiforme |
1.6% |
Vomiting |
1.5% |
Chemotherapy |
1.4% |
Colorectal Cancer |
1.4% |
Breast Cancer Metastatic |
1.3% |
Colon Cancer |
1.2% |
Supplementation Therapy |
1.2% |
|
Vomiting |
12.8% |
Thrombocytopenia |
11.9% |
White Blood Cell Count Decreased |
10.3% |
Sepsis |
6.3% |
Pyrexia |
6.3% |
Pneumonia |
5.9% |
Pulmonary Embolism |
5.8% |
Death |
4.2% |
Osteonecrosis |
4.1% |
Weight Decreased |
4.1% |
Renal Failure Acute |
3.4% |
Respiratory Failure |
3.4% |
Rash |
3.1% |
Septic Shock |
3.1% |
White Blood Cell Count Increased |
2.8% |
Tooth Extraction |
2.8% |
Urinary Tract Infection |
2.6% |
Renal Failure |
2.5% |
Multiple Myeloma |
2.3% |
Platelet Count Decreased |
2.2% |
|
Interacting |
General Anaesthesia |
20.4% |
Musculoskeletal Pain |
10.6% |
Osteotomy |
10.6% |
Pain |
10.6% |
Drug Use For Unknown Indication |
8.8% |
Adrenogenital Syndrome |
5.3% |
Convulsion |
5.3% |
Maintenance Of Anaesthesia |
5.3% |
Neuralgia |
4.4% |
Induction Of Anaesthesia |
3.5% |
Epilepsy |
2.7% |
Multiple Myeloma |
2.7% |
Auricular Swelling |
1.8% |
Gastric Sarcoma |
1.8% |
Prophylaxis |
1.8% |
Anaesthesia |
0.9% |
Anxiety Disorder |
0.9% |
Breast Cancer |
0.9% |
Hypertension |
0.9% |
Pneumonia |
0.9% |
|
Malaise |
20.0% |
Sinus Tachycardia |
20.0% |
Myotonia |
13.3% |
Thrombocytopenia |
13.3% |
Clostridium Difficile Colitis |
6.7% |
Demyelinating Polyneuropathy |
6.7% |
Platelet Count Decreased |
6.7% |
Pulmonary Embolism |
6.7% |
Urticaria |
6.7% |
|